Aurinia Pharmaceuticals Inc. (AUPH) Key Metrics
AUPH valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $2.20B
- Enterprise value
- $1.84B
- P/E (TTM)
- 7.2
- Forward P/E
- 11.8
- PEG ratio
- —
- Price / sales
- 7.1 10-yr median 20.3
- Price / book
- 3.6 10-yr median 3.6
- EV / EBITDA
- 10.0
- Dividend yield
- —
- Beta
- 1.61
AUPH key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAUPH valuation Price multiples at each fiscal year-end price.
AUPH returns How much profit the business earns on the capital it uses.
AUPH per-share figures Results divided by the shares outstanding at year-end.
AUPH financial health Debt, liquidity and how easily interest is covered.
AUPH efficiency & capital use Working capital cycle and where the cash goes.
AUPH valuation history
AUPH returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AUPH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AUPH cash returned to shareholders
AUPH price vs earnings per share
AUPH key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $2.21B | $1.31B | $1.29B | $613.1M | $2.96B | $1.64B | $1.88B | $578.2M | $348.6M | $74.1M |
| Enterprise value | $1.89B | $1.03B | $1.03B | $231.8M | $2.50B | $1.25B | $1.59B | $452.5M | $191.0M | $46.5M |
| P/E ratio | 7.7 | 228.2 | — | — | — | — | — | — | — | — |
| Price / sales | 7.8 | 5.6 | 7.3 | 4.6 | 64.9 | 32.7 | — | — | 829.9 | 428.3 |
| Price / book | 3.8 | 3.5 | 3.4 | 1.5 | 6.2 | 4.0 | 6.3 | 5.1 | 2.1 | 2.1 |
| Price / free cash flow | 16.3 | 29.8 | — | — | — | — | — | — | — | — |
| Price / operating cash flow | 16.3 | 29.6 | — | — | — | — | — | — | — | — |
| EV / sales | 6.7 | 4.4 | 5.9 | 1.7 | 54.8 | 24.9 | — | 977.3 | 454.7 | 268.9 |
| EV / EBITDA | 14.8 | 32.6 | — | — | — | — | — | — | — | — |
| EV / free cash flow | 14.0 | 23.4 | — | — | — | — | — | — | — | — |
| Earnings yield | 13.0% | 0.4% | −6.1% | −17.6% | −6.1% | −6.3% | −4.7% | −11.1% | −20.3% | −31.4% |
| Free cash flow yield | 6.1% | 3.4% | −2.7% | −13.0% | −5.4% | −4.7% | −3.4% | −8.9% | −11.8% | −25.3% |
| Shareholder yield (dividends + buybacks) | 4.4% | 3.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $15.95 | $8.98 | $8.99 | $4.32 | $22.87 | $13.83 | $20.26 | $6.82 | $4.53 | $2.10 |
| Per share | ||||||||||
| Revenue per share | $2.04 | $1.61 | $1.23 | $0.94 | $0.35 | $0.42 | $0.00 | $0.01 | $0.01 | $0.00 |
| Earnings per share | $2.07 | $0.04 | −$0.54 | −$0.76 | −$1.40 | −$0.87 | −$0.95 | −$0.76 | −$0.92 | −$0.66 |
| Operating cash flow per share | $0.98 | $0.30 | −$0.23 | −$0.56 | −$1.22 | −$0.59 | −$0.68 | −$0.61 | −$0.54 | −$0.53 |
| Free cash flow per share | $0.98 | $0.30 | −$0.24 | −$0.56 | −$1.23 | −$0.65 | −$0.68 | −$0.61 | −$0.54 | −$0.53 |
| Cash per share | $2.87 | $2.45 | $2.45 | $2.74 | $3.60 | $3.36 | $3.29 | $1.48 | $2.25 | $1.12 |
| Book value per share | $4.19 | $2.58 | $2.64 | $2.86 | $3.70 | $3.44 | $3.21 | $1.33 | $2.15 | $1.02 |
| Tangible book value per share | $4.16 | $2.55 | $2.60 | $2.81 | $3.64 | $3.36 | $3.11 | $1.18 | $1.97 | $0.58 |
| Capex per share | $0.00 | $0.00 | $0.01 | $0.00 | $0.01 | $0.06 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | $0.54 | $0.54 | $0.68 | $0.06 | $0.07 | $0.07 | $0.07 | $0.00 | $0.21 | $0.34 |
| Shares outstanding | 138.7M | 146.2M | 143.2M | 141.9M | 129.4M | 118.5M | 93.0M | 84.8M | 76.9M | 35.3M |
| Change in shares outstanding | −5.1% | +2.1% | +0.9% | +9.7% | +9.2% | +27.4% | +9.7% | +10.2% | +118.1% | +9.7% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 59.9% | 1.5% | −19.9% | −24.5% | −40.8% | −29.1% | −43.0% | −46.1% | −70.2% | −83.3% |
| Return on invested capital (ROIC) | 58.9% | −3.2% | −97.1% | −383.8% | −721.5% | −951.7% | — | — | −450.4% | −199.4% |
| Return on assets (ROA) | 44.1% | 1.0% | −15.3% | −21.3% | −35.9% | −26.1% | −37.6% | −38.2% | −57.4% | −51.4% |
| Return on tangible assets | 38.4% | 1.1% | −14.4% | −23.3% | −33.8% | −22.6% | −28.0% | −48.1% | −40.3% | −56.2% |
| Free cash flow margin | 47.8% | 18.8% | −19.5% | −59.6% | −349.1% | −154.0% | — | — | — | — |
| Income quality (OCF / net income) | 0.47 | 7.72 | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $74.8M | $79.4M | $97.6M | $8.1M | $8.7M | $8.4M | $6.9M | $118,000 | $15.9M | $12.1M |
| Cash & short-term investments | $398.0M | $358.5M | $350.5M | $389.4M | $466.1M | $398.3M | $306.0M | $125.9M | $173.5M | $39.6M |
| Net debt | −$323.2M | −$279.1M | −$252.9M | −$381.3M | −$457.3M | −$389.9M | −$299.1M | −$125.7M | −$157.6M | −$27.6M |
| Debt / equity | 0.13 | 0.21 | 0.26 | 0.02 | 0.02 | 0.02 | 0.02 | 0.00 | 0.10 | 0.34 |
| Debt / assets | 0.10 | 0.14 | 0.18 | 0.02 | 0.02 | 0.02 | 0.02 | 0.00 | 0.08 | 0.21 |
| Net debt / EBITDA | −2.53 | −8.80 | — | — | — | — | — | — | — | — |
| Current ratio | 5.25 | 4.57 | 5.50 | 9.60 | 12.63 | 13.11 | 27.90 | 18.30 | 21.50 | 5.22 |
| Quick ratio | 4.76 | 4.17 | 4.99 | 9.06 | 12.15 | 12.67 | 27.90 | 18.30 | 21.52 | 5.22 |
| Interest coverage | 24.2 | -1.0 | -33.0 | -21.8 | -341.7 | -19.7 | — | -25.1 | -67.0 | -845.0 |
| Working capital | $398.2M | $348.8M | $347.6M | $396.4M | $472.7M | $387.4M | $303.8M | $125.6M | $167.1M | $33.5M |
| Invested capital | $258.1M | $98.4M | $125.1M | $24.1M | $21.8M | $17.8M | −$513,000 | −$13.2M | $8.1M | $8.4M |
| Tangible asset value | $577.6M | $373.1M | $373.0M | $399.0M | $470.7M | $398.4M | $289.7M | $100.0M | $151.6M | $20.4M |
| Net current asset value | $321.7M | $273.4M | $254.7M | $377.1M | $449.0M | $363.5M | $289.4M | $99.6M | $151.1M | $20.4M |
| Graham number | $13.97 | $1.51 | — | — | — | — | — | — | — | — |
| Graham net-net per share | $2.03 | $1.59 | $1.52 | $2.44 | $3.27 | $2.95 | $3.02 | $1.09 | $1.94 | $0.53 |
| Capital allocation | ||||||||||
| Share buybacks (net) | $98.2M | $40.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends + buybacks / free cash flow | 72.5% | 91.2% | — | — | — | — | — | — | — | — |
| Capex / revenue | 0.1% | 0.1% | 0.4% | 0.2% | 3.3% | 14.7% | 31.8% | 16.2% | 6.0% | 14.5% |
| Capex / operating cash flow | 0.2% | 0.6% | — | — | — | — | — | — | — | — |
| Capex / depreciation | 0.03 | 0.01 | 0.06 | 0.11 | 0.54 | 5.36 | 0.09 | 0.05 | 0.02 | 0.02 |
| Stock-based compensation / revenue | 5.2% | 13.4% | 25.8% | 24.1% | 68.5% | 34.8% | 2,331.4% | 1,481.6% | 1,010.0% | 799.4% |
| R&D / revenue | 11.5% | 8.8% | 28.3% | 33.6% | 112.1% | 100.4% | 16,624.5% | 8,937.8% | 8,078.6% | 8,401.2% |
| SG&A / revenue | 36.0% | 73.2% | 111.1% | 146.5% | 375.9% | 194.1% | 7,024.5% | 2,953.3% | 2,880.0% | 4,028.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 50.3 | 47.1 | 39.1 | 39.3 | 61.9 | 1.5 | 335.7 | 128.5 | 84.7 | 140.3 |
| Days of inventory on hand | 474.4 | 510.0 | 831.5 | 1,420.2 | 5,562.5 | 101.0 | — | — | -19,892.3 | 0.1 |
| Days payables outstanding | 47.5 | 61.5 | 95.6 | 224.5 | 1,089.6 | 24.6 | 38.7 | 47.8 | 1,211,070.0 | 225,478.8 |
| Cash conversion cycle (days) | 477.2 | 495.6 | 774.9 | 1,235.1 | 4,534.7 | 77.9 | 297.0 | 80.7 | -1,230,877.6 | -225,338.4 |
| Receivables turnover | 7.26 | 7.76 | 9.34 | 9.28 | 5.90 | 239.23 | 1.09 | 2.84 | 4.31 | 2.60 |
| Payables turnover | 7.69 | 5.94 | 3.82 | 1.63 | 0.33 | 14.83 | 9.42 | 7.63 | 0.00 | 0.00 |
| Inventory turnover | 0.77 | 0.72 | 0.44 | 0.26 | 0.07 | 3.61 | — | — | — | 4,000.00 |
| Asset turnover | 0.43 | 0.43 | 0.34 | 0.26 | 0.09 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $39.0M | $30.3M | $18.8M | $14.4M | $7.7M | $209,500 | $292,500 | $163,000 | $97,500 | $66,500 |
| Average payables | $4.2M | $4.8M | $3.7M | $3.5M | $3.3M | $3.4M | $5.6M | $5.4M | $3.3M | $2.5M |
| Average inventory | $42.5M | $39.5M | $32.2M | $22.0M | $16.6M | $13.9M | — | — | −$54,500 | $1 |
| Intangibles / total assets | 0.5% | 0.8% | 0.9% | 1.4% | 1.5% | 2.0% | 2.7% | 8.6% | 7.4% | 27.3% |
Computed from AUPH's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
AUPH valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Aurinia Pharmaceuticals traded at 7.7 times earnings. Based on the latest twelve months, the trailing P/E is 7.2 and the forward P/E is 11.8. Aurinia Pharmaceuticals earned a return on equity of 59.9% and a return on invested capital of 58.9% in fiscal 2025. It ended the year with $74.8 million of debt and $398.0 million in cash and short-term investments, a net cash position of $323.2 million. It returned $98.2 million to shareholders: $0 in dividends and $98.2 million in share buybacks, 72% of free cash flow. The share count rose 293.1% from 35.3M to 138.7M over 9 years.
See the AUPH income statement, the AUPH chart for price history, or the AUPH stock overview for the latest quote and news.
AUPH key metrics FAQ
What is Aurinia Pharmaceuticals's P/E ratio?
Aurinia Pharmaceuticals's trailing P/E ratio is 7.2 based on the last twelve months of earnings (as of October 17, 2026), and its forward P/E is 11.8. At the end of fiscal 2025 it was 7.7.
What is Aurinia Pharmaceuticals's EV/EBITDA?
Aurinia Pharmaceuticals's enterprise value was 14.8 times EBITDA at the end of fiscal 2025 (enterprise value $1.9 billion, EBITDA $127.8 million); the current EV/EBITDA is 10.0.
What is Aurinia Pharmaceuticals's return on equity?
Aurinia Pharmaceuticals's return on equity (ROE) was 59.9% in fiscal 2025: net income of $287.2 million on average shareholders' equity of $479.4 million.
What is Aurinia Pharmaceuticals's ROIC?
Aurinia Pharmaceuticals's return on invested capital was 58.9% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals had total debt of $74.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.13 and more cash than debt.
Does Aurinia Pharmaceuticals buy back its shares?
Yes. Aurinia Pharmaceuticals spent $98.2 million on net share repurchases in fiscal 2025 Shares outstanding changed −5.1% over the year, to 138.7M..
What is Aurinia Pharmaceuticals's free cash flow yield?
Aurinia Pharmaceuticals generated $135.4 million of free cash flow in fiscal 2025, a free cash flow yield of 6.1% on its market value at year-end ($2.2 billion).
What is Aurinia Pharmaceuticals's current ratio?
Aurinia Pharmaceuticals's current ratio was 5.25 at the end of fiscal 2025: current assets were 5.25 times current liabilities.